Cargando…

Clinical and microbiologic characteristics of cefotaxime-non-susceptible Enterobacteriaceae bacteremia: a case control study

BACKGROUND: Cefotaxime plays an important role in the treatment of patients with bacteremia due to Enterobacteriaceae, although cefotaxime resistance is reported to be increasing in association with extended-spectrum β-lactamase (ESBL) and AmpC β-lactamase (AmpC). METHODS: We conducted a case-contro...

Descripción completa

Detalles Bibliográficos
Autores principales: Noguchi, Taro, Matsumura, Yasufumi, Yamamoto, Masaki, Nagao, Miki, Takakura, Shunji, Ichiyama, Satoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5219717/
https://www.ncbi.nlm.nih.gov/pubmed/28061869
http://dx.doi.org/10.1186/s12879-016-2150-6
_version_ 1782492508951937024
author Noguchi, Taro
Matsumura, Yasufumi
Yamamoto, Masaki
Nagao, Miki
Takakura, Shunji
Ichiyama, Satoshi
author_facet Noguchi, Taro
Matsumura, Yasufumi
Yamamoto, Masaki
Nagao, Miki
Takakura, Shunji
Ichiyama, Satoshi
author_sort Noguchi, Taro
collection PubMed
description BACKGROUND: Cefotaxime plays an important role in the treatment of patients with bacteremia due to Enterobacteriaceae, although cefotaxime resistance is reported to be increasing in association with extended-spectrum β-lactamase (ESBL) and AmpC β-lactamase (AmpC). METHODS: We conducted a case-control study in a Japanese university hospital between 2011 and 2012. We assessed the risk factors and clinical outcomes of bacteremia due to cefotaxime-non-susceptible Enterobacteriaceae (CTXNS-En) and analyzed the resistance mechanisms. RESULTS: Of 316 patients with Enterobacteriaceae bacteremia, 37 patients with bacteremia caused by CTXNS-En were matched to 74 patients who had bacteremia caused by cefotaxime-susceptible Enterobacteriaceae (CTXS-En). The most common CTXNS-En was Escherichia coli (43%), followed by Enterobacter spp. (24%) and Klebsiella spp. (22%). Independent risk factors for CTXNS-En bacteremia included previous infection or colonization of CTXNS-En, cardiac disease, the presence of intravascular catheter and prior surgery within 30 days. Patients with CTXNS-En bacteremia were less likely to receive appropriate empirical therapy and to achieve a complete response at 72 h than patients with CTXS-En bacteremia. Mortality was comparable between CTXNS-En and CTXS-En patients (5 vs. 3%). CTXNS-En isolates exhibited multidrug resistance but remained highly susceptible to amikacin and meropenem. CTX-M-type ESBLs accounted for 76% of the β-lactamase genes responsible for CTXNS E. coli and Klebsiella spp. isolates, followed by plasmid-mediated AmpC (12%). Chromosomal AmpC was responsible for 89% of CTXNS Enterobacter spp. isolates. CONCLUSIONS: CTXNS-En isolates harboring ESBL and AmpC caused delays in appropriate therapy among bacteremic patients. Risk factors and antibiograms may improve the selection of appropriate therapy for CTXNS-En bacteremia. Prevalent mechanisms of resistance in CTXNS-En were ESBL and chromosomal AmpC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-016-2150-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5219717
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-52197172017-01-10 Clinical and microbiologic characteristics of cefotaxime-non-susceptible Enterobacteriaceae bacteremia: a case control study Noguchi, Taro Matsumura, Yasufumi Yamamoto, Masaki Nagao, Miki Takakura, Shunji Ichiyama, Satoshi BMC Infect Dis Research Article BACKGROUND: Cefotaxime plays an important role in the treatment of patients with bacteremia due to Enterobacteriaceae, although cefotaxime resistance is reported to be increasing in association with extended-spectrum β-lactamase (ESBL) and AmpC β-lactamase (AmpC). METHODS: We conducted a case-control study in a Japanese university hospital between 2011 and 2012. We assessed the risk factors and clinical outcomes of bacteremia due to cefotaxime-non-susceptible Enterobacteriaceae (CTXNS-En) and analyzed the resistance mechanisms. RESULTS: Of 316 patients with Enterobacteriaceae bacteremia, 37 patients with bacteremia caused by CTXNS-En were matched to 74 patients who had bacteremia caused by cefotaxime-susceptible Enterobacteriaceae (CTXS-En). The most common CTXNS-En was Escherichia coli (43%), followed by Enterobacter spp. (24%) and Klebsiella spp. (22%). Independent risk factors for CTXNS-En bacteremia included previous infection or colonization of CTXNS-En, cardiac disease, the presence of intravascular catheter and prior surgery within 30 days. Patients with CTXNS-En bacteremia were less likely to receive appropriate empirical therapy and to achieve a complete response at 72 h than patients with CTXS-En bacteremia. Mortality was comparable between CTXNS-En and CTXS-En patients (5 vs. 3%). CTXNS-En isolates exhibited multidrug resistance but remained highly susceptible to amikacin and meropenem. CTX-M-type ESBLs accounted for 76% of the β-lactamase genes responsible for CTXNS E. coli and Klebsiella spp. isolates, followed by plasmid-mediated AmpC (12%). Chromosomal AmpC was responsible for 89% of CTXNS Enterobacter spp. isolates. CONCLUSIONS: CTXNS-En isolates harboring ESBL and AmpC caused delays in appropriate therapy among bacteremic patients. Risk factors and antibiograms may improve the selection of appropriate therapy for CTXNS-En bacteremia. Prevalent mechanisms of resistance in CTXNS-En were ESBL and chromosomal AmpC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-016-2150-6) contains supplementary material, which is available to authorized users. BioMed Central 2017-01-07 /pmc/articles/PMC5219717/ /pubmed/28061869 http://dx.doi.org/10.1186/s12879-016-2150-6 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Noguchi, Taro
Matsumura, Yasufumi
Yamamoto, Masaki
Nagao, Miki
Takakura, Shunji
Ichiyama, Satoshi
Clinical and microbiologic characteristics of cefotaxime-non-susceptible Enterobacteriaceae bacteremia: a case control study
title Clinical and microbiologic characteristics of cefotaxime-non-susceptible Enterobacteriaceae bacteremia: a case control study
title_full Clinical and microbiologic characteristics of cefotaxime-non-susceptible Enterobacteriaceae bacteremia: a case control study
title_fullStr Clinical and microbiologic characteristics of cefotaxime-non-susceptible Enterobacteriaceae bacteremia: a case control study
title_full_unstemmed Clinical and microbiologic characteristics of cefotaxime-non-susceptible Enterobacteriaceae bacteremia: a case control study
title_short Clinical and microbiologic characteristics of cefotaxime-non-susceptible Enterobacteriaceae bacteremia: a case control study
title_sort clinical and microbiologic characteristics of cefotaxime-non-susceptible enterobacteriaceae bacteremia: a case control study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5219717/
https://www.ncbi.nlm.nih.gov/pubmed/28061869
http://dx.doi.org/10.1186/s12879-016-2150-6
work_keys_str_mv AT noguchitaro clinicalandmicrobiologiccharacteristicsofcefotaximenonsusceptibleenterobacteriaceaebacteremiaacasecontrolstudy
AT matsumurayasufumi clinicalandmicrobiologiccharacteristicsofcefotaximenonsusceptibleenterobacteriaceaebacteremiaacasecontrolstudy
AT yamamotomasaki clinicalandmicrobiologiccharacteristicsofcefotaximenonsusceptibleenterobacteriaceaebacteremiaacasecontrolstudy
AT nagaomiki clinicalandmicrobiologiccharacteristicsofcefotaximenonsusceptibleenterobacteriaceaebacteremiaacasecontrolstudy
AT takakurashunji clinicalandmicrobiologiccharacteristicsofcefotaximenonsusceptibleenterobacteriaceaebacteremiaacasecontrolstudy
AT ichiyamasatoshi clinicalandmicrobiologiccharacteristicsofcefotaximenonsusceptibleenterobacteriaceaebacteremiaacasecontrolstudy